{
  "id": "63f02e1bf36125a426000016",
  "type": "yesno",
  "question": "Was AAVS3 developed for hemophilia A?",
  "ideal_answer": "No. AAVS3 was developed for hemophilia B.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35857660"
  ],
  "snippets": [
    {
      "text": "Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35857660",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: FLT180a (verbrinacogene setparvovec) is a liver-directed adeno-associated virus (AAV) gene therapy that uses a synthetic capsid and a gain-of-function protein to normalize factor IX levels in patients with hemophilia B",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35857660",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}